Mean cost per subject for 1 year of treatment
. | Arm A: rHuEPO + rHuG-CSF . | . | . | . | ||
|---|---|---|---|---|---|---|
| Treatment . | 52 weeks of follow-up with rHuEPO +/− rHuG-CSF . | 52 weeks of follow-up but stopped rHuEPO + rHuG-CSF after week 12 . | Total subjects who completed 52 weeks of follow-up . | Arm B: supportive care; n = 24 . | ||
| Transfusions, mean ± SEM | 2085 ± 3000 | 9651 ± 5989 | 7489 ± 6295 | 7579 ± 4934 | ||
| Median | 1059 | 7897 | 6567 | 7067 | ||
| Range | 0-8024 | 1347-19 520 | 0-19 520 | 0-20 527 | ||
| rHuEPO + rHuG-CSF, mean ± SEM | 35 666 ± 6705 | 19 263 ± 12 942 | 23 949 ± 13 644 | 0 | ||
| Median | 36 877 | 9999 | 23 222 | — | ||
| Range | 23 222-41 366 | 7613-38 794 | 7613-41 366 | — | ||
| Disease follow-up, mean ± SEM | 172 ± 221 | 126 ± 194 | 139 ± 198 | 580 ± 1443 | ||
| Median | 96 | 33 | 34 | 84 | ||
| Range | 0-607 | 0-602 | 0-607 | 0-5755 | ||
| Only hospital stays, mean ± SEM | 0 | 0 | 0 | 419 ± 1425 | ||
| Median | 0 | 0 | 0 | 0 | ||
| Range | 0-0 | 0-0 | 0-0 | 0-5489 | ||
| Total, mean ± SEM | 37 922 ± 8 064 | 29 040 ± 9607 | 31 577 ± 9 888 | 8158 ± 5723 | ||
| Median | 37 447 | 27 832 | 28 256 | 7816 | ||
| Range | 25 194-49 018 | 14 887-41 197 | 14 887-49 018 | 53-26 282 | ||
. | Arm A: rHuEPO + rHuG-CSF . | . | . | . | ||
|---|---|---|---|---|---|---|
| Treatment . | 52 weeks of follow-up with rHuEPO +/− rHuG-CSF . | 52 weeks of follow-up but stopped rHuEPO + rHuG-CSF after week 12 . | Total subjects who completed 52 weeks of follow-up . | Arm B: supportive care; n = 24 . | ||
| Transfusions, mean ± SEM | 2085 ± 3000 | 9651 ± 5989 | 7489 ± 6295 | 7579 ± 4934 | ||
| Median | 1059 | 7897 | 6567 | 7067 | ||
| Range | 0-8024 | 1347-19 520 | 0-19 520 | 0-20 527 | ||
| rHuEPO + rHuG-CSF, mean ± SEM | 35 666 ± 6705 | 19 263 ± 12 942 | 23 949 ± 13 644 | 0 | ||
| Median | 36 877 | 9999 | 23 222 | — | ||
| Range | 23 222-41 366 | 7613-38 794 | 7613-41 366 | — | ||
| Disease follow-up, mean ± SEM | 172 ± 221 | 126 ± 194 | 139 ± 198 | 580 ± 1443 | ||
| Median | 96 | 33 | 34 | 84 | ||
| Range | 0-607 | 0-602 | 0-607 | 0-5755 | ||
| Only hospital stays, mean ± SEM | 0 | 0 | 0 | 419 ± 1425 | ||
| Median | 0 | 0 | 0 | 0 | ||
| Range | 0-0 | 0-0 | 0-0 | 0-5489 | ||
| Total, mean ± SEM | 37 922 ± 8 064 | 29 040 ± 9607 | 31 577 ± 9 888 | 8158 ± 5723 | ||
| Median | 37 447 | 27 832 | 28 256 | 7816 | ||
| Range | 25 194-49 018 | 14 887-41 197 | 14 887-49 018 | 53-26 282 | ||
Costs are given in euros (€1 = $1.20). Patient populations are as follows: 52 weeks of follow-up with rHuEPO +/− rHuG-CSF, n = 6; 52 weeks of follow-up with rHuEOP + rHuG-CSF stopped after week 12, n = 15; and total subjects who completed 52 weeks of follow-up, n = 21.—indicates not applicable.